Percutaneous Transvalvular Microaxial Flow Pump Support in Cardiology

Area of Science:

• Cardiology
• Medical Devices
• Interventional Cardiology

Background:

• The Impella device is a microaxial flow pump used for cardiogenic shock, left ventricular unloading, high-risk PCI, VT ablation, and RV failure.
• While observational studies show Impella improves hemodynamic parameters, significant complication rates (bleeding, ischemia, hemolysis, stroke) exist.
• Current evidence from large, powered randomized controlled trials (RCTs) on Impella's impact on outcomes and complications is insufficient.

Purpose of the Study:

• To review the current applications, benefits, and complications of the Impella device.
• To highlight the need for more robust clinical evidence from ongoing and planned large-scale RCTs.

Main Methods:

• Review of existing literature on Impella device usage, including observational studies and smaller RCTs.
• Identification of ongoing and planned large RCTs investigating Impella in various clinical scenarios.

Main Results:

• Impella use is associated with increased mean arterial pressure, cardiac output, and tissue perfusion.
• High rates of bleeding (up to 44%), ischemic complications (up to 18%), hemolysis (up to 32%), and stroke (up to 13%) are reported.
• Small RCTs in cardiogenic shock have not demonstrated improved mortality with Impella compared to intra-aortic balloon pump.

Conclusions:

• Despite growing Impella use, robust data from large RCTs are lacking to definitively establish its efficacy and safety.
• Several large RCTs are underway or planned to address these evidence gaps in cardiogenic shock, left ventricular unloading, and high-risk PCI.